PURPOSE: Multibeam intensity modulated radiation therapy (IMRT) enhances the therapeutic index by increasing the dosimetric coverage of the targeted tumor tissues while minimizing volumes of adjacent organs receiving high doses of RT. The tradeoff is that a greater volume of lung is exposed to low doses of RT, raising concern about the risk of radiation pneumonitis (RP). METHODS AND MATERIALS: Between July 2010 and January 2013, patients with node-positive breast cancer received inverse-planned, multibeam IMRT to the breast or chest wall and regional nodes, including the internal mammary nodes (IMNs). The primary endpoint was feasibility, predefined by dosimetric treatment planning criteria. Secondary endpoints included the incidence of RP grade 3 or greater and changes in pulmonary function measured with the Common Terminology Criteria for Adverse Events version 3.0 scales, pulmonary function tests and community-acquired pneumonia questionnaires, obtained at baseline and 6 months after IMRT. Clinical follow-up was every 6 months for up to 5 years. RESULTS: Median follow-up was 53.4 months (range, 0-82 months). Of 113 patients enrolled, 104 completed follow-up procedures. Coverage of the breast or chest wall and IMN was comprehensive (median 48.1 Gy and 48.9 Gy, respectively). The median volume of lung receiving a high dose (V20Gy) and a low dose (V5) was 29% and 100%, respectively. The overall rate of respiratory toxicities was 10.6% (11/104), including 1 grade 3 RP event (0.96%). No differences were found in pulmonary function test or community-acquired pneumonia scores after IMRT. The 5-year rates of locoregional recurrence-free, disease-free, and overall survival were 93.2%, 63.6%, and 80.3%, respectively. CONCLUSIONS: Multibeam IMRT in patients with breast cancer receiving regional nodal irradiation was dosimetrically feasible, based on early treatment planning criteria. Despite the large volume of lung receiving low-dose RT, the incidence of grade 3 RP was remarkably low, justifying inverse-planned IMRT as a treatment modality for patients with high-risk breast cancer in whom conventional RT techniques prove inadequate.
PURPOSE: Multibeam intensity modulated radiation therapy (IMRT) enhances the therapeutic index by increasing the dosimetric coverage of the targeted tumor tissues while minimizing volumes of adjacent organs receiving high doses of RT. The tradeoff is that a greater volume of lung is exposed to low doses of RT, raising concern about the risk of radiation pneumonitis (RP). METHODS AND MATERIALS: Between July 2010 and January 2013, patients with node-positive breast cancer received inverse-planned, multibeam IMRT to the breast or chest wall and regional nodes, including the internal mammary nodes (IMNs). The primary endpoint was feasibility, predefined by dosimetric treatment planning criteria. Secondary endpoints included the incidence of RP grade 3 or greater and changes in pulmonary function measured with the Common Terminology Criteria for Adverse Events version 3.0 scales, pulmonary function tests and community-acquired pneumonia questionnaires, obtained at baseline and 6 months after IMRT. Clinical follow-up was every 6 months for up to 5 years. RESULTS: Median follow-up was 53.4 months (range, 0-82 months). Of 113 patients enrolled, 104 completed follow-up procedures. Coverage of the breast or chest wall and IMN was comprehensive (median 48.1 Gy and 48.9 Gy, respectively). The median volume of lung receiving a high dose (V20Gy) and a low dose (V5) was 29% and 100%, respectively. The overall rate of respiratory toxicities was 10.6% (11/104), including 1 grade 3 RP event (0.96%). No differences were found in pulmonary function test or community-acquired pneumonia scores after IMRT. The 5-year rates of locoregional recurrence-free, disease-free, and overall survival were 93.2%, 63.6%, and 80.3%, respectively. CONCLUSIONS: Multibeam IMRT in patients with breast cancer receiving regional nodal irradiation was dosimetrically feasible, based on early treatment planning criteria. Despite the large volume of lung receiving low-dose RT, the incidence of grade 3 RP was remarkably low, justifying inverse-planned IMRT as a treatment modality for patients with high-risk breast cancer in whom conventional RT techniques prove inadequate.
Authors: Pehr A Lind; Lawrence B Marks; Timothy A Jamieson; Dennis L Carter; James J Vredenburgh; Rodney J Folz; Leonard R Prosnitz Journal: Cancer Date: 2002-06-01 Impact factor: 6.860
Authors: Min Rao; Wensha Yang; Fan Chen; Ke Sheng; Jinsong Ye; Vivek Mehta; David Shepard; Daliang Cao Journal: Med Phys Date: 2010-03 Impact factor: 4.071
Authors: Sharon H Giordano; Yong-Fang Kuo; Jean L Freeman; Thomas A Buchholz; Gabriel N Hortobagyi; James S Goodwin Journal: J Natl Cancer Inst Date: 2005-03-16 Impact factor: 13.506
Authors: L Milas; N R Hunter; B Kurdoglu; K A Mason; R E Meyn; L C Stephens; L J Peters Journal: Cancer Chemother Pharmacol Date: 1995 Impact factor: 3.333
Authors: S Murty Goddu; Summer Chaudhari; Maria Mamalui-Hunter; Olga L Pechenaya; David Pratt; Sasa Mutic; Imran Zoberi; Sam Jeswani; Simon N Powell; Daniel A Low Journal: Int J Radiat Oncol Biol Phys Date: 2009-03-15 Impact factor: 7.038
Authors: Jose G Bazan; Dominic DiCostanzo; Karen Hock; Sachin Jhawar; Karla Kuhn; Kylee Lindsey; Kayla Tedrick; Erin Healy; Sasha Beyer; Julia R White Journal: Front Oncol Date: 2021-03-11 Impact factor: 6.244
Authors: Heejoo Ko; Jee Suk Chang; Jin Young Moon; Won Hee Lee; Chirag Shah; Jin Sup Andy Shim; Min Cheol Han; Jong Geol Baek; Ryeong Hwang Park; Yong Bae Kim; Jin Sung Kim Journal: Front Oncol Date: 2021-04-12 Impact factor: 6.244
Authors: Guang Li; Wei Lu; Kyle O'Grady; Iris Yan; Ellen Yorke; Laura I Cervino Arriba; Simon Powell; Linda Hong Journal: J Appl Clin Med Phys Date: 2022-01-20 Impact factor: 2.102